Jane, aged 27, diagnosed with anxiety disorder and depression, left work on January 13, 2015. She had a history of anxiety and depression dating back to her teens. During the onset of her claim, Jane’s family physician tried several medications, including citalopram and sertraline, both of which were ineffective and caused side effects such as dizziness and drowsiness. Jane also had a history of non-adherence due to the limited benefits.
Jane began weaning herself off her medications and started working with a rehabilitation professional to whom she was referred by her long-term disability (LTD) insurer. The consultant recommended a pharmacogenomic test. In the subsequent appointment with her psychiatrist (November 23, 2015), he approved adjusting Jane’s medications according to the recommendations outlined in the pharmacogenomic report. Jane started taking Citalopram again but at a much lower dose (of 5 mg) and was to increase very slowly every three to four weeks (to a maximum dose of 20 mg).
Impact: Jane began her new treatment on November 23, 2015 and late December, she reported that her mood had improved, and her side effects had decreased. Jane’s treating psychologist confirmed the improvement in her mood. Jane experienced an improvement in her symptoms within one month after receiving the results of her report. Jane returned to work in March 2016 (3.5 months after receiving her report).
The Personal Medicine Profile can be used to select which medical treatment will benefit the patient, i.e. finding the right medication, in the right dose for the right person.
The diagnosis is still to be made by the doctor. Do not change any medication without consulting your doctor.
Personal Medicine Profile™
PMP is a once only investment. Use it when new medicine is prescribed.
We take good care of your personal data according to GDPR (EU) with our Security by Design set-up.
Pharmacogenomic Test Group. (352 individuals)
Control Group. (333 individuals)
Proportion of patients experiencing at least one medication change. 2, 4, 8, 12 weeks.
PGx-guided treatment of depression and anxiety
All depression and anxiety medication changes were recorded. Number of Medication Change, New Medication and Medication Discontinued (all P < 0.0001) was significantly higher in the pharmacogenetic-guided group compared to the control group during the 2-12 week follow-up visits. Dose Adjustments were similar between groups (P=0.7). For more details we refer to the article: Bradley et al. 2018.
Source: Paul Bradley et al. Improved Efficacy with Targeted Pharmacogenetic guided Treatment of Patients with Depression and Anxiety – a Randomized Clinical Trial Demonstrating Clinical Utility. Journal of Psychiatric Research, 96(2018) 100-107
We are all different
The practice of medicine has always been about treating each person as an individual patient. For a long time, clinicians have observed that patients with the same diagnosis may respond differently to the same medical treatment.
Advances in technology have made it possible to identify genetic variations determining the effectiveness of commonly prescribed medications.
Personal Medicine Profile relies on this very technology.
We Protect Your Privacy
We promise to keep your personal and genetic information confidential. Here’s what we do:
Your biological sample is destroyed after quality control. We do not sell it or hand it over to third parties.
Throughout our processes we handle your sample anonymously. Only authorized personnel have access to your sample.
You have full access to your data and you can choose to share it with your Doctor or Pharmacy
We build our system based on “security by design” to protect your data from harm
Genetelligence focus on services, research and development in the field of personalized medicine. Therefore, we work with a wide range of private and public institutions. Please, feel free to contact us for possible cooperation.